Keywords: AstraZeneca, Rigel Pharma, R256, Chronic asthma, Fostamatinib, Arthritis
AstraZeneca gains rights to Rigel's asthma candidate R256
Article | 20 June 2012
Anglo Swedish drug major AstraZeneca (LSE: AZN) and signed an exclusive global license accord with USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
